US Patent No: 5,190,765

Number of patents in Portfolio can not be more than 2000

Therapy delayed

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ALZA CORPORATIONPALO ALTO, CA848

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Huynh, Hoa T Fremont, CA 15 322
Jao, Frank San Jose, CA 20 207
McChesney, Kathy Cupertino, CA 4 96
Wat, Pamela K Santa Clara, CA 7 110
Wong, Patrick S L Burlingame, CA 109 2524

Cited Art

Patent Info (Count) # Cites Year
 
ALZA CORPORATION (10)
4,318,400 Medical infusor 54 1980
4,327,725 Osmotic device with hydrogel driving member 533 1980
4,612,008 Osmotic device with dual thermodynamic activity 225 1984
4,842,867 Pulsed drug delivery of doxylamine 31 1986
4,765,989 Osmotic device for administering certain drugs 121 1986
4,783,337 Osmotic system comprising plurality of members for dispensing drug 172 1986
4,946,687 Dosage form for treating cardiovascular diseases 16 1988
4,950,486 Dosage form for treating cardiovascular diseases 20 1988
4,948,592 Pulsed drug delivery 27 1989
4,966,769 Method for delivering dosage form for diltiazem 18 1989
 
BANKERS TRUST COMPANY (1)
4,863,744 Intestine drug delivery 52 1987

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
ALZA CORPORATION (13)
6,440,457 Method of administering antidepressant dosage form 7 1993
6,491,945 Hydrocodone therapy 12 1994
5,906,832 Method for treating epilepsies 18 1995
5,660,861 Effective therapy for epilepsies 26 1995
5,866,161 Hydrocodone therapy 12 1996
5,955,103 Dosage form comprising antiepileptic drug 11 1997
5,876,750 Effective therapy for epilepsies 7 1997
5,863,558 Effective therapy for epilepsies 10 1997
6,764,697 System for delaying drug delivery up to seven hours 7 1998
6,368,626 Controlled delivery of active agents 18 1999
8,246,986 Drug coating providing high drug loading 0 2004
8,084,059 Antidepressant dosage form 0 2006
8,226,979 Drug coating providing high drug loading and methods for providing the same 0 2011
 
G. D. SEARLE & CO. (7)
6,225,325 Use of alkylated iminosugars to treat multidrug resistance 21 1998
6,410,054 Immediate release eplerenone compositions 10 1999
6,515,028 Glucamine compounds for treating hepatitis virus infections 2 2000
6,558,707 Immediate release eplerenone compositions 3 2002
6,534,093 Immediate release eplerenone compositions 4 2002
6,495,165 Eplerenone compositions having improved bioavailability 6 2002
6,747,149 Glucamine salts for treating hepatitis virus infections 0 2002
 
UNITED THERAPEUTICS CORPORATION (3)
6,689,759 Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy 5 2000
6,545,021 Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections 5 2000
7,612,093 Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy 0 2005
 
ANDRX LABS, LLC (2)
5,837,379 Once daily pharmaceutical tablet having a unitary core 37 1997
6,485,748 Once daily pharmaceutical tablet having a unitary core 0 1997
 
ANDRX PHARMACEUTICALS, INC. (2)
5,922,352 Once daily calcium channel blocker tablet having a delayed release core 15 1997
6,524,620 Diltiazem controlled release formulation and method of manufacture 3 1998
 
DURECT CORPORATION (2)
8,420,120 Oral drug delivery system 0 2012
8,354,124 Oral drug delivery system 0 2012
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (2)
6,342,249 Controlled release liquid active agent formulation dosage forms 26 1999
6,596,314 Controlled release liquid active agent formulation dosage forms 8 2001
 
INTARCIA THERAPEUTICS, INC. (2)
7,959,938 Polyoxaester suspending vehicles for use with implantable delivery systems 0 2006
8,114,430 Polyoxaester suspending vehicles for use with implantable delivery systems 1 2011
 
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (2)
8,241,667 Dual controlled release osmotic device 0 2005
8,329,217 Dual controlled release dosage form 0 2006
 
ALTA CORPORATION (1)
6,855,334 Controlled delivery of active agents 5 2001
 
ANDA SR PHARMACEUTICALS ICN. (1)
5,419,917 Controlled release hydrogel formulation 27 1994
 
JANSSEN PHARMACEUTICA N.V. (1)
7,736,668 System for delaying drug delivery up to seven hours 0 2003
 
JPMORGAN CHASE BANK, N.A. (1)
7,887,841 Chronotherapeutic dosage forms and methods of treatment using chronotherapy 0 2004
 
PENWEST PHARMACEUTICALS CO. (1)
8,389,008 Delayed release dosage forms 0 2004
 
POLICHEM S.A. (1)
RE39239 Methods for treating early morning pathologies 0 2002
 
VALEANT INTERNATIONAL BERMUDA (1)
7,108,866 Chronotherapeutic diltiazem formulations and the administration thereof 1 2000
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (3)
6,809,083 Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections 4 1999
6,706,282 Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones 0 1999
6,592,902 Controlled release eplerenone compositions 3 2002